We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beckman Invests in UK Microbiology Market
Product News

Beckman Invests in UK Microbiology Market

Beckman Invests in UK Microbiology Market
Product News

Beckman Invests in UK Microbiology Market


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Beckman Invests in UK Microbiology Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beckman Coulter has launched two automated systems in the UK to ease rapidly increasing workloads in microbiology and virology departments. The DxN VERIS Molecular Diagnostics system, for same-day molecular viral load testing, and the MicroScan Microbiology Systems for microorganism identification (ID) and antimicrobial susceptibility testing (AST), both rapidly and accurately identify therapeutic pathways for patient management. This high-throughput testing significantly streamlines laboratory workflows, and reduces time to patient therapy diagnoses. The launch marks the advent of a significant investment in the UK microbiology market by Beckman Coulter with further product introductions scheduled. 

The UK launch of the systems was celebrated with a showcase event - the first in a new series of educational events designed to provide a platform for interested parties to learn about new technologies. At the initial event, attendees had the opportunity to; speak to individuals using the new automated platforms, evaluate data in the form of presentations, and speak with technical experts to answer queries and gain a greater depth of understanding. 

Duncan Whittaker, Laboratory Manager Virology at the Sheffield Teaching Hospital NHS Trust, spoke at the event about his experience with the DxN VERIS - which provides fast and accurate viral load assays by consolidating extraction, amplification and detection onto a single platform. “The DxN VERIS is the kind of instrumentation that will help the laboratory to meet long terms goals for improved services with faster turnaround times and greater productivity,” he commented. The easy-to-use DxN VERIS system saves both hands-on time and space in the laboratory. Results are available rapidly - facilitating fast decision making and positively impacting patient treatment. Duncan confirmed, “Training staff is very quick and straightforward, taking just 20 minutes. Initial comments have been that faster results for certain viral load assays could be life-saving in some instances.” 

Attendees also heard from Michael Dawson, Senior Biomedical Scientist, from the William Harvey Hospital where two MicroScan WalkAway 96 Plus systems are in use as part of the East Kent Microbiology Service. The systems have improved workflow and streamlined processes through the rapid delivery of ID and AST with gold-standard accuracy. The easy-to-use walkaway systems allow simultaneous processing of conventional, rapid, and specialty panels. In addition, the MicroScan offers true Minimum Inhibitory Concentration (MIC) technology with visual read capability, which enables the detection of emerging resistance in real-time, without reliance on historical data.

Michael spoke about his Trust’s decision to move to the MicroScan platform for AST in particular. “For us the need to move to an automated microbial screening system was clear. Our previous multipoint testing methods, supported by disc diffusion testing, were non-reproducible, unreliable and inaccurate. In addition to the lack of standardisation, they were time consuming and whilst we screened for many agents, MIC determination required a further manual method.”   

Source:

Story from Beckman Coulter. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.

Advertisement